The Statutory Landscape as It Actually Stands

This page is analysis and advocacy — it is not legal advice

Read this before you read anything else on the page. What follows is a research and policy brief. It is written to be used by regulators, legislators, counsel and industry researchers as an argument, and the argument is stated at full strength because a hedged brief is useless to the people who need it. It is not a legal opinion, it is not a clearance, and it is not advice to you. Three things make that more than a formality. First, cannabinoid law varies enormously by state: a compound that is lawful under federal law can be a felony in the jurisdiction where you live, ship, store or sell, and state analogue statutes, total-intoxicant caps and compound-by-name bans operate independently of the federal scheme described here. Second, this area of law is changing quickly — the federal definition of hemp itself was rewritten in late 2025 with a delayed effective date, state legislatures have moved in both directions in every recent session, and agency positions have shifted. Anything written here can be overtaken by an amendment, a rule, or a decision. Third, an argument that a substance is not a controlled substance analogue is a defence, not a permission: it is something a defendant says after being charged, and the fact that it is a good argument does not mean nobody will be charged. Do not make a business decision, a product decision or a personal decision on the basis of this page. Get your own lawyer, licensed in your own jurisdiction, and give them the actual facts. This overview page in particular is a map, not a compliance opinion: it tells you which questions decide a case, not what the answer is for your product.

• Not legal advice, and no lawyer-client relationship arises from reading it.
• Federal lawfulness does not imply state lawfulness — check your own state, and the states you ship to.
• The law described here is in motion; a delayed federal effective date sits in the middle of it.
• A strong non-analogue argument is a defence to a charge, not immunity from one.
• Nothing here is medical advice either, and nothing here is an endorsement of using any compound.

The definition that created the market

The 2018 Farm Bill did not legalise cannabis. It did something narrower and, as it turned out, far more consequential: it wrote a definition. Hemp, at 7 U.S.C. § 1639o(1), is the plant Cannabis sativa L. and any part of that plant, including the seeds, and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis. Congress then amended the Controlled Substances Act to match: the marijuana definition at 21 U.S.C. § 802(16) was amended to exclude hemp as so defined, and the tetrahydrocannabinols entry in schedule I at 21 U.S.C. § 812(c) was amended to exclude tetrahydrocannabinols in hemp. Three features of that drafting did the work. The definition is a list that expressly includes cannabinoids and isomers. It sets its threshold against one named analyte, delta-9 THC. And it expresses that threshold as a percentage of dry weight rather than as a quantity in a finished product. Everything that has happened in the hemp-derived cannabinoid market since is downstream of those three choices.

• The operative words are "derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" — isomers are named in the statute.
• The threshold names delta-9 THC specifically, not tetrahydrocannabinols as a class.
• The metric is percent of dry weight, which is a concentration in plant or biomass terms, not a dose in a product.
• The 0.3 percent figure has no pharmacological basis; it descends from a 1970s taxonomic convenience for distinguishing fibre cultivars.

Sources: United States Congress 2018 · United States Code 2018 · United States Code 2018 · United States Code 2018

What the definition does not cover

The definition is silent on four questions that turn out to matter more than anything it says. It does not say what happens to a cannabinoid that was obtained from a compliant hemp plant and then chemically altered — the material is plant-derived in origin, but the molecule in the bottle was not the molecule in the plant. It does not address cannabinoids other than delta-9 THC at all, so a cannabinoid that is intoxicating but not delta-9 THC falls outside the only quantitative limit in the definition. It does not distinguish between raw agricultural commodity and finished consumer product, so a percentage-by-dry-weight threshold has to be applied to gummies, beverages and vape liquids for which "dry weight" is close to meaningless as a concept. And it says nothing about dose: a product can satisfy 0.3 percent by dry weight and still contain tens of milligrams of an intoxicant per unit, because the denominator is large. Each of these silences became a commercial category.

• Converted and isomerised cannabinoids: plant-derived in origin, not plant-produced as a molecule.
• Non-delta-9 intoxicating cannabinoids: outside the only number in the definition.
• Finished products: a dry-weight percentage is a poor fit for a beverage.
• Dose: the percentage limits concentration, not the quantity in a unit a person consumes.

Sources: United States Code 2018

The measurement question that actually decides compliance

Two laboratories can test the same material honestly and report it as compliant and as non-compliant, because they are measuring different things. The 2018 definition names delta-9 THC. But cannabis does not principally contain delta-9 THC; it contains tetrahydrocannabinolic acid (THCA), the carboxylated biosynthetic product, which loses carbon dioxide on heating to give delta-9 THC. A delta-9-only assay on unheated material reports a small number. A total-THC assay decarboxylates first, or computes the potential delta-9 arithmetically from the measured THCA, and reports a much larger one. The conversion is not one-for-one: THCA is the heavier molecule, so the potential delta-9 from a given mass of THCA is a fraction of that mass, and the total-THC figure is conventionally the measured delta-9 plus that fraction of the measured THCA. Which convention a rule adopts decides whether a given lot of biomass is hemp or marijuana, and it is the single most consequential technical choice in cannabinoid regulation. The 2018 federal definition and the USDA sampling regime moved toward a total-THC reading for the plant, while product-level enforcement and much state law continued to operate on delta-9 alone. The 2025 redefinition resolves the question federally by adopting a total tetrahydrocannabinols standard that expressly includes THCA.

• Delta-9-only on undecarboxylated material understates potential potency; total THC does not.
• The molar mass difference between THCA and delta-9 THC is why total THC is a weighted sum rather than a simple addition.
• A rule that names one analyte regulates that analyte, not the intoxicant class.
• The arithmetic itself is set out on the total-THC page of the certificate-of-analysis shelf.

Sources: United States Code 2018 · United States Congress 2025 · Congressional Research Service 2025

DEA's interim final rule and "synthetically derived tetrahydrocannabinols" contested

On 21 August 2020 the Drug Enforcement Administration published an interim final rule codifying the Farm Bill amendments in its regulations. One sentence in it has done more work than the rest of the document combined: all synthetically derived tetrahydrocannabinols remain schedule I controlled substances. The rule's reasoning is that the hemp definition is limited to material derived from the plant, so for a synthetically derived tetrahydrocannabinol the delta-9 concentration is simply not the determining factor. The agency's position has been restated in correspondence since, including on the acetate esters. The difficulty is that the rule does not define "synthetically derived", and the phrase can bear at least three readings: a molecule built from non-cannabis feedstocks; a molecule that did not itself occur in the source plant, however it was obtained; or a molecule produced by any chemical step outside the plant, including a single-step rearrangement of a plant-derived precursor. The commercial hemp-derived market lives entirely inside the gap between the second and third readings, and no court has yet supplied an authoritative definition. This is the most important genuinely unsettled question in the field, and it is unsettled — a page that told you otherwise would be wrong.

Contested — caveat. The agency's position is clear; its content is not. "Synthetically derived" has no regulatory definition and no controlling judicial construction. The DEA correspondence on the acetate esters is known here through secondary reporting rather than from the letter itself, and is cited as unverified.

Sources: Drug Enforcement Administration 2020 · Code of Federal Regulations 2020 · Drug Enforcement Administration (reported) 2023* · United States Court of Appeals for the Fourth Circuit 2024

AK Futures v. Boyd Street Distro — the authority in the other direction

The Ninth Circuit in AK Futures LLC v. Boyd Street Distro, LLC, 35 F.4th 682 (9th Cir. 2022), held that hemp-derived delta-8 THC products fall within the plain text of the 2018 hemp definition and are lawful, so that the plaintiff's marks on delta-8 vape products were entitled to trademark protection. The court reasoned from the statutory text: delta-8 THC is a cannabinoid and an isomer, both expressly named in the definition, and the product contained not more than 0.3 percent delta-9 THC, which is the only quantitative condition the definition imposes. Because the court found the text unambiguous it declined to defer to agency interpretation, adding that the DEA's own view as it understood it aligned with its reading. This is a genuine and significant data point against the broad reading of the interim final rule, and it should be treated as one rather than explained away. Its limits should also be stated honestly. It arose in a trademark and preliminary-injunction posture rather than a criminal or scheduling one; it binds only the Ninth Circuit; it did not squarely decide what "synthetically derived" means; and it expressly left room for regulation by the states. The Fourth Circuit in Anderson v. Diamondback Investment Group later declined to read the interim final rule as compelling a finding that THC-O is unlawful, which cuts in a similar direction from a different circuit and a different posture.

• Holding: hemp-derived delta-8 THC is within the statutory definition of hemp; lawful for trademark purposes.
• Method: plain text, with isomers and cannabinoids expressly named in the definition.
• Limits: Ninth Circuit only; civil intellectual-property posture; no holding on "synthetically derived".
• Companion: the Fourth Circuit in Anderson declined to treat the interim final rule as dispositive against THC-O.

Sources: United States Court of Appeals for the Ninth Circuit 2022 · United States Court of Appeals for the Fourth Circuit 2024 · United States Code 2018 · Drug Enforcement Administration 2020

Hemp Industries Association v. DEA and the natural-versus-synthetic line

The older Ninth Circuit authority matters because it establishes a structural limit on agency action rather than a result about one compound. In Hemp Industries Association v. DEA, 357 F.3d 1012 (9th Cir. 2004), the court held that the DEA could not, by interpretive rule, reach naturally occurring cannabinoids in non-psychoactive hemp products that Congress had not scheduled. The reasoning runs through congressional intent: Congress scheduled tetrahydrocannabinols at a time when synthetic THC had recently been made in a laboratory, and it did so without repealing the marijuana provisions and their exemptions for stalk, fibre and seed — from which the court inferred that the natural plant was to be dealt with by the marijuana provisions and the schedule I tetrahydrocannabinols entry was aimed at the synthetic article. The narrow holding is about non-psychoactive hemp foods. The transferable holding is procedural and is the one that keeps being cited: an agency cannot expand the reach of a schedule by interpretation, and if it wants a substance controlled it must schedule it through the statutory process.

Sources: United States Court of Appeals for the Ninth Circuit 2004 · United States Code 2018 · United States Code 2018

The market the definition produced

A definition that limited one analyte by percentage of dry weight, in a plant that makes over a hundred structurally related compounds, produced a national market in intoxicating products that are not delta-9 THC in the plant sense: isomers of delta-9 such as delta-8 and delta-10, the acidic precursor THCA sold as unheated material, the acetate esters, the hydrogenated cannabinoid HHC, and the naturally occurring side-chain homologs with chains longer than pentyl. That market is real in scale, it developed tested and labelled distribution channels in most states, and it developed them without any federal product-safety framework governing the conversions involved, because no such framework was written. Both halves of that sentence matter to the policy argument: the market's existence is what makes prohibition costly, and its lack of a safety framework is what makes prohibition attractive. A brief that reports only the first half will not persuade anyone who has read the second.

• Isomers of delta-9 THC (delta-8, delta-10) and their own isomeric by-products.
• The acidic precursor THCA, sold as material whose potency is realised on heating.
• Acetate esters and hydrogenated cannabinoids, which do not occur in the plant at all.
• Naturally occurring side-chain homologs — the butyl, hexyl, heptyl and octyl series.
• Product forms the 2018 definition never contemplated: beverages, gummies, vape liquids, inhalable concentrates.

Sources: Radwan MM 2021 · ElSohly MA 2005 · Citti C 2019 · Linciano P 2019 · Linciano P 2020

The 2025 appropriations development

On 12 November 2025 Congress enacted H.R. 5371, the continuing appropriations package, section 781 of which rewrites the definition of hemp. The redefinition moves from a delta-9-only percentage to a total tetrahydrocannabinols standard that expressly includes tetrahydrocannabinolic acid and extends to other cannabinoids designated as having, or being marketed as having, similar effects; it imposes a quantifiable threshold on finished products expressed as 0.4 mg total THC per container, with container defined as the innermost wrapping or vessel in direct contact with the product; and it excludes from the definition cannabinoids that are not naturally produced by the plant or that are synthesised outside it. The provision carries a one-year delayed effective date of 12 November 2026. Two things about that are worth stating precisely because they are widely misreported. The threshold is per container, not per serving — the operator's source brief and much of the trade press say per serving, and that is wrong, and the difference is large for multi-serving packages. And the provision was enacted, not merely proposed: the one-year delay is a transition period, not a contingency. The provision is analysed in detail on its own page.

Sources: United States Congress 2025 · Congressional Research Service 2025 · Arnold & Porter 2025

The states have moved independently, and in both directions

Federal analysis is necessary and is nowhere near sufficient. State law on hemp-derived cannabinoids has diverged sharply and continues to move every session, and because possession and sale are prosecuted overwhelmingly at state level, state law is usually the law that decides what happens to a person. The patterns are recognisable. Some states have banned named compounds outright, sometimes by listing them in a state controlled-substances schedule. Some have adopted a total-intoxicant or total-THC cap, which makes the identity of the cannabinoid irrelevant. Some have adopted milligram caps per serving and per package, which is the same regulatory form the new federal provision uses at a much higher number — Minnesota, for example, permits not more than 5 mg of any tetrahydrocannabinol per serving and 50 mg per package for edibles and 10 mg per beverage container. Some have channelled hemp-derived intoxicants into a licensed adult-use system. Some have their own analogue statutes, drafted more broadly than the federal one. And at least one large producing state came within a veto of a near-total ban: Texas Senate Bill 3 in 2025 would have prohibited consumable hemp products containing any cannabinoid other than CBD or CBG, and was vetoed on 22 June 2025. The practical consequence for anyone reading this: the federal argument on these pages can be entirely correct and entirely beside the point in your jurisdiction.

• Compound-by-name bans in state schedules — the federal analogue argument does not touch these.
• Total-intoxicant or total-THC caps — potency-blind, and indifferent to which cannabinoid it is.
• Milligram-per-serving and per-package caps — the same form as the new federal rule, at 10 to 100 times the number.
• Channelling into licensed adult-use systems.
• State analogue statutes, some broader than 21 U.S.C. § 802(32).

Sources: Minnesota Statutes 2022 · Texas Legislature 2025 · Office of the Governor of Texas (Greg Abbott) 2025 · United States Court of Appeals for the Ninth Circuit 2022

What is genuinely unsettled contested

It is worth being explicit about the difference between a question this shelf argues and a question nobody can currently answer. The table separates them. Where the answer is unsettled, no amount of confident drafting by anyone — including this shelf — changes that.

Contested — caveat. This table is a snapshot taken on 27 September 2026 and will decay. Treat any row as a prompt to check current law, not as a conclusion.

Sources: United States Court of Appeals for the Ninth Circuit 2022 · Drug Enforcement Administration 2020 · United States Code 1986 · United States Congress 2025 · Congressional Research Service 2025